Lobbying registration dated 2026-04-02
Registrant: David Goodman
Client: Pharmascience Inc.
Targeted institutions:
Global Affairs Canada (GAC)
Transport Canada (TC)
House of Commons
Prime Minister's Office (PMO)
Public Services and Procurement Canada (PSPC)
Health Canada (HC)
Finance Canada (FIN)
Innovation, Science and Economic Development Canada (ISED)
Government funding received:
Institution: Canada Economic Development for Quebec Regions
Amount: 100000.00
Institution: Innovation, Science and Economic Development Canada (ISED)
Amount: null
Institution: Investissement Québec
Amount: null
Lobbying activity details:
Discussion on the opioid crisis and the Health minister's expectations from pharmaceutical manufacturers
Policies aimed at reinforcing pharmaceutical supply chain.
Discussion regarding the launch of new branded product in the rare disease space
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products.
Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.
Policies aimed at facilitating generic drug repurposing.
Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.